POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Clinical trials for POST-POLYCYTHEMIA VERA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-POLYCYTHEMIA VERA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-POLYCYTHEMIA VERA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill tested for rare blood cancers
Disease control Recruiting nowThis is a first-in-human study to test the safety and find the right dose of an experimental oral drug called PRT12396 for people with certain rare blood cancers. It will enroll about 100 adults with high-risk polycythemia vera or myelofibrosis. The main goal is to see how well t…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 21:41 UTC
-
New hope for tough blood cancer
Disease control Recruiting nowThis study is testing whether a drug called tasquinimod can help control myelofibrosis, a serious bone marrow cancer. It will be given either by itself or alongside an existing drug (ruxolitinib) to 33 adults whose current treatments aren't working well enough. The main goals are…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:19 UTC
-
New hope for blood cancer patients who failed standard treatment
Disease control Recruiting nowThis early-stage trial is testing a new oral medication called AJ1-11095 for adults with myelofibrosis, a serious bone marrow cancer. The study is for patients whose disease didn't respond well to or came back after standard JAK2 inhibitor treatment. Researchers will determine th…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Ajax Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Drug trial extends hope for patients with rare blood disorders
Disease control Recruiting nowThis study continues treatment for 400 people with rare blood cancers who are already benefiting from the drug bomedemstat in earlier trials. Its main goal is to collect long-term safety information and see how well the drug continues to control the disease over time. The study i…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for blood cancer patients with dangerous low platelets
Disease control Recruiting nowThis study is testing an investigational drug called pacritinib against standard care treatments for adults with myelofibrosis, a serious bone marrow cancer, who also have dangerously low platelet counts. The main goals are to see if pacritinib can reduce spleen size and ease dis…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Massive 5,000-Person study launches to map the journey of rare blood cancers
Knowledge-focused Recruiting nowThis is a long-term observational study aiming to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. who have been diagnosed with an MPN for at least five years, collecting information from …
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:40 UTC